With regards to access, PSMA PET is currently not standard of care in Canada, and aside from access through the PREP registry, there are no prostate cancer-specific PET radiopharmaceuticals approved for routine clinical use by Health Canada. This evidence concerns the gene FOLH1 and Familial prostate cancer.